GlassScriptPhysician profile
Shivani Sharma
NPI 1215342902
$2,398.73
in general payments reported to CMS, 2019-2025
20 companies · $1,093 in 2025
The $1,093 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.24 · 2020: $337 · 2021: $573 · 2022: $205 · 2023: $114 · 2024: $23.52 · 2025: $1,093.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,230.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,229.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $410.95 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $388.84 | 2020-2025 | Spravato |
| Abbvie INC. | $363.57 | 2024-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $305.34 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $208.21 | 2019-2021 | |
| Vanda Pharmaceuticals INC. | $190.35 | 2021-2022 | |
| Lundbeck LLC | $79.84 | 2020-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $73.59 | 2021-2025 | Austedo Xr |
| Tms Neurohealth Centers INC. | $62.28 | 2025 | Tms Neurohealth Centers INC. |
| Bausch Health US, LLC | $58.55 | 2025 | Wellbutrin, Aplenzin |
| Supernus Pharmaceuticals, INC. | $46.76 | 2025 | Qelbree |
| Takeda Pharmaceuticals U.S.A., INC. | $38.32 | 2021 | |
| Axsome Therapeutics, INC. | $31.79 | 2025 | Auvelity |
| Neurocrine Biosciences, INC. | $25.33 | 2022 | |
| Biogen, INC. | $21.32 | 2025 | Zurzuvae |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $20.22 | 2021 | |
| Acadia Pharmaceuticals INC | $19.47 | 2025 | Nuplazid |
| Indivior INC. | $18.76 | 2022 | |
| Alkermes, INC. | $17.81 | 2022 | |
| Noven Therapeutics, LLC | $17.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivani Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.